September is Ovarian Cancer Awareness Month. According to the American Cancer Society, a woman’s risk of getting ovarian cancer during her lifetime is about 1 in 75 and her risk of dying from the disease is approximately 1 in 100. Fortunately, there are now more treatment options than ever to improve the rate of survival including chemotherapy, immunotherapy and targeted therapy.
At GoPath, we have developed a number of diagnostic tool both to detect a hereditary link to ovarian cancer as well as tests to aid clinicians’ treatment recommendations. For hereditary testing, we offer our BRCAnow® series, which can analyze up to 30 genes associated with hereditary ovarian and breast cancer. To evaluate how a patient’s ovarian cancer is progressing, we offer diagnostic testing for BRAF, KRAS, PTEN loss, PIK3CA and OncoTarget™ -- our comprehensive, NGS-based assay that detects genetic alterations of whole exons in well-characterized genes.
Here are some online resources to visit to learn more about ovarian cancer:
National Ovarian Cancer Coalition: ovarian.org
Ovarian Cancer Research Fund Alliance: ocrfa.org
Bright Pink: brightpink.org
Ovarian Cancer Awareness: ovariancancerawareness.org